Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Sleep Disorders and Multiple Sclerosis: A Clinical and Polysomnography Study.
Genome-wide association study of multiple sclerosis confirms a novel locus at 5p13.1.
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
From "Wheelchair Circuit" to "Wheelchair Assessment Instrument for People with Multiple Sclerosis": Reliability and Validity Analysis of a Test to Assess Driving Skills in Manual Wheelchair Users With Multiple Sclerosis.
[Pharmacological properties and clinical efficacy of fingolimod hydrochloride (Imusera®/Gilenya®) for the treatment of multiple sclerosis].
Two discreet subsets of CD8 T cells modulate PLP(91-110) induced experimental autoimmune encephalomyelitis in HLA-DR3 transgenic mice.
Frequency of obsessive-compulsive disorder in patients with multiple sclerosis: A cross-sectional study.
A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01.
Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon.
Biochemical Markers of Autoimmune Diseases of the Nervous System.
A qualitative exploration of the impact of a 12-week group exercise class for those moderately affected with multiple sclerosis.
Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis.
Autoinflammatory grey matter lesions in humans: cortical encephalitis, clinical disorders, experimental models.
Alemtuzumab (Lemtrada) - NICE says yes in final draft guidance
Comment on the letter by Messori et al. (European Journal of Neurology 2013; 20: e131).
Predicted structure of MIF/CD74 and RTL1000/CD74 complexes.
New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis
New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis
Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study.
Unraveling the secrets of white matter - Bridging the gap between cellular, animal and human imaging studies.
Medicare Part D payments for neurologist-prescribed drugs.
Influence of pregnancy on neuromyelitis optica spectrum disorder.
Mapi Pharma granted United States patent covering glatiramer depot for multiple sclerosis
Optic neuritis in a child with biotinidase deficiency: case report and literature review.
Diagnosis of exclusion: a case report of probable glatiramer acetate-induced eosinophilic myocarditis.

Pages